8th WORKSHOP: FOOD AND DRUG SAFETY AND QUALITY, (pp.167–175)
АУТОР / AUTHOR(S): S. Jakhotia 
, B. Nastasijević , G. Joksić , S. S. Reddy , G. B. Reddy
DOI: 10.46793/8FDSQ.ILD1SJ
САЖЕТАК / ABSTRACT:
Chronic hyperglycemia in diabetes leads to macro and microvascular complications. An increase in the aldose reductase (ALR2) activity, accumulation of sorbitol, accumulation of advanced glycation end-products (AGEs), and inflammation lead to cellular damage, ultimately resulting in complications. ALR2 inhibition has been a consideration to treat/manage diabetic complications, but most of the ALR2 inhibitors are not free of side effects. As a part of our work to find better ALR2 inhibitors, we found that extracts of Gentiana lutea exhibited ALR2 inhibitory potential in vitro. We have also discovered the anti-atherosclerotic potential of G. lutea when supplemented its root powder (2% in the AIN-93 diet) to diabetic rats. Our very recent work suggests the reno-protective effect of G. lutea supplementation (0.2% and 2% in the AIN-93 diet). Here, we summarize our work on the role of G. lutea in preventing macrovascular complications of diabetes like atherosclerosis and microvascular complications like nephropathy and, hence, its potential as an adjunct therapy for diabetic complications.
КЉУЧНЕ РЕЧИ / KEYWORDS:
ПРОЈЕКАТ / ACKNOWLEDGEMENT:
ЛИТЕРАТУРА / REFERENCES:
[1] F. G. Scurt, J. Menne, S. Brandt, A. Bernhardt, P. R. Mertens, H. Haller, C. Chatzikyrkou, R. S. Committee, Kidney international reports, 2019, 4, 1373-1386.
[2]S. Nagini, P. R. Kallamadi, K. K. K. Tanagala, G. B. Reddy, Oncology research, 2024, 32, 1287-1308.
[3]P. A. Kumar, G. B. Reddy, Experimental eye research, 2007, 85, 739-740.
[4]M. Kumar, S. Choudhary, P. K. Singh, O. Silakari, Future medicinal chemistry,2020, 12, 1327-1358.
[5]C. Akileshwari, P. Muthenna, B. Nastasijevic, G. Joksic, J. M. Petrash, G. B. Reddy Experimental diabetes research, 2012, 147965.
[6] R. Kesavan, S. Chandel, S. Upadhyay, R. Bendre, R. Ganugula, U. R. Potunuru, H. Giri, G. Sahu, P. U. Kumar, G. B. Reddy, G. Joksic, A. K. Bera, M. Dixit, Nutrition, metabolism, and cardiovascular diseases: NMCD, 2016, 26, 293-301.
[7] K. K. Kalahasti, C. U. Kumar, M. Nagaraju, J. M. Petrash, S. S. Reddy, G. B. Reddy, Chemico-biological interactions, 2024, 390, 110889.
[8] P. S. Chitra, D. Chaki, N. K. Boiroju, T. R. Mokalla, A. K. Gadde, S. G. Agraharam, G. B. Reddy, Experimental eye research, 2020, 200, 108230.
[9] A. Snow, B. Shieh, K. C. Chang, A. Pal, P. Lenhart, D. Ammar, P. Ruzycki, S. Palla, G. B. Reddy, J. M. Petrash, Chemico-biological interactions, 2015, 234, 247-253.
[10] M. A. Patil, P. Suryanarayana, U. K. Putcha, M. Srinivas, G. B. Reddy, Oxidative medicine and cellular longevity, 2014, 463264.
[11] T. Morii, H. Fujita, T. Narita, T. Shimotomai, H. Fujishima, N. Yoshioka, H. Imai, M. Kakei, S. Ito, Journal of diabetes and its complications,2003, 17, 11-15.
[12] F. Y. Chow, D. J. Nikolic-Paterson, R. C. Atkins, G. H. Tesch, Nephrology, dialysis, transplantation, 2004, 19, 2987-2996.
[13] P. Roy-Chaudhury, B. Wu, G. King, M. Campbell, A. M. Macleod, N.E. Haites, J. G. Simpson, D. A. Power, Kidney international, 1996, 49, 127-134.
[14] S Jakhotia, G. Raghu, G Joksic, S. S. Reddy, G. B. Reddy, Indian Journal of Experimental Biology, 2024 (in press)